VEGF therapy: A timely retreat

Cardiovascular Research

Volumn 83, Issue 4, 2009, Pages 611-612

  Alfranca, Arántzazu ^a  

^a CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; DOXYCYCLINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PARVOVIRUS VECTOR; PLATELET DERIVED GROWTH FACTOR; VASCULOTROPIN;

ANGIOGENESIS; BIOSAFETY; CAPILLARY DENSITY; EDITORIAL; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE THERAPY; HEART MUSCLE ISCHEMIA; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENE;

ANIMALS; DEPENDOVIRUS; DOXYCYCLINE; GENE EXPRESSION; HUMANS; ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; RECOMBINANT PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 68949099629     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp228     Document Type: Editorial

References (13)

1. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-660.
2. Tongers J, Roncalli JG, Losordo DW. Therapeutic angiogenesis for critical limb ischemia: microvascular therapies coming of age. Circulation 2008; 118:9-16.
3. Markkanen JE, Rissanen TT, Kivelä A, Ylä-Herttuala S. Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart-gene therapy. Cardiovasc Res 2005;65:656-664.
4. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000;102:898-901.
5. Mineur P, Colige AC, Deroanne CF, Dubail J, Kesteloot F, Habraken Y et al. Newly identified biologically active and proteolysis-resistant VEGF-A isoform VEGF111 is induced by genotoxic agents. J Cell Biol 2007;179: 1261-1273.
6. Ozawa CR, Banfi A, Glazer NL, Thurston G, Springer ML, Kraft P et al. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest 2004;113:516-527.
7. Tafuro S, Ayuso E, Zacchigna S, Zentilin L, Moimas S, Dore F et al. Inducible adeno-associated virus vectors promote functional angiogenesis in adult organisms via regulated vascular endothelial growth factor expression. Cardiovasc Res 2009;83:663-671.
8. Dor Y, Djonov V, Abramovitch R, Itin A, Fishman GI, Carmeliet P et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J 2002;21:1939-1947.
9. Arsic N, Zentilin L, Zacchigna S, Santoro D, Stanta G, Salvi A et al. Induction of neovascularization by combines VEGF and angiopoietin-1 gene transfer using AAV vectors. Mol Ther 2003;7:450-459.
10. Korpisalo P, Karvinen H, Rissanen TT, Kilpijoki J, Marjomäki V, Baluk P et al. Vascular endothelial growth factor-A and platelet-derived growth factor-B combination gene therapy prolongs angiogenic effects via recruitment of interstitial mononuclear cells and paracrine effects rather than improved pericyte coverage of angiogenic vessels. Circ Res 2008;103:1092-1099.
11. Shimpo M, Ikeda U, Maeda Y, Takahashi M, Miyashita H, Mizukami H et al. AAV-mediated VEGF gene transfer into skeletal muscle stimulates angiogenesis and improves blood flow in a rat hindlimb ischemia model. Cardiovasc Res 2002;52:993-1001.
12. Pajusola K, Künnapuu J, Vuorikoski S, Soronen J, André H, Pereira T et al. Stabilized HIF-1a is superior to VEGF for angiogenesis in skeletal muscle via adeno-associated gene transfer. FASEB J 2005;19:1365-1367.
13. Patel TH, Kimura H, Weiss CR, Semenza GL, Hofmann LV. Constitutively active HIF-1a improves prefusion and arterial remodeling in an endovascular model of limb ischemia. Cardiovasc Res 2005;68:144-154.